PC
ALNY icon

PointState Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

PointState Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-30,000
Closed -$5.09M – 68
2021
Q4 		$5.09M Buy
30,000
+18,000
+150% +$3.35M 0.08% 87
2021
Q3 		$2.27M Buy
+12,000
New +$2.25M 0.04% 115

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PointState Capital's ALNY Position: Q1 2022 in Review

PointState Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2022, closing a stake of 30,000 shares — an estimated $5.09M sold.

PointState Capital first reported a position in ALNY in Q3 2021 and held it in 2 quarters. The position peaked at $5.09M in Q4 2021. 444 funds tracked by Wall St. Rank hold ALNY as of Q1 2022.

  • PointState Capital reported no remaining Alnylam Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • PointState Capital sold 30,000 Alnylam Pharmaceuticals shares in Q1 2022, an estimated $5.09M.
  • PointState Capital first reported a position in Alnylam Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • PointState Capital's Alnylam Pharmaceuticals position peaked at $5.09M in Q4 2021.
  • 444 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2022.

Based on PointState Capital's 13F filing for Q1 2022, filed 13 May 2022.